BRAF V600E
|
Ovarian Serous Adenocarcinoma
|
BRAF V600E
|
Ovarian Serous Adenocarcinoma
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA2 mutation
|
Ovarian Serous Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
|
olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
|
KRAS G12V
|
Ovarian Serous Adenocarcinoma
|
KRAS G12V
|
Ovarian Serous Adenocarcinoma
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria
|
KRAS G12D
|
Ovarian Serous Adenocarcinoma
|
KRAS G12D
|
Ovarian Serous Adenocarcinoma
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
KRAS G12A
|
Ovarian Serous Adenocarcinoma
|
KRAS G12A
|
Ovarian Serous Adenocarcinoma
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
Choline elevation
|
Ovarian Serous Adenocarcinoma
|
Choline elevation
|
Ovarian Serous Adenocarcinoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
SERPINE1 expression
|
Ovarian Serous Adenocarcinoma
|
SERPINE1 expression
|
Ovarian Serous Adenocarcinoma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA1 mutation
|
Ovarian Serous Adenocarcinoma
|
AZD1775 Sensitive: C4 – Case Studies
|
AZD1775 Sensitive: C4 – Case Studies
|
GOPC-ROS1 fusion
|
Ovarian Serous Adenocarcinoma
|
GOPC-ROS1 fusion
|
Ovarian Serous Adenocarcinoma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
ER Y537N
|
Ovarian Serous Adenocarcinoma
|
ER Y537N
|
Ovarian Serous Adenocarcinoma
|
fulvestrant Sensitive: C4 – Case Studies
|
fulvestrant Sensitive: C4 – Case Studies
|
TMB-H + MSH6 F1088fs
|
Ovarian Serous Adenocarcinoma
|
TMB-H + MSH6 F1088fs
|
Ovarian Serous Adenocarcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
BRCA2 mutation
|
Ovarian Serous Adenocarcinoma
|
BRCA2 mutation
|
Ovarian Serous Adenocarcinoma
|
LY2606368 + LY3023414 Sensitive: D – Preclinical
|
LY2606368 + LY3023414 Sensitive: D – Preclinical
|
BRAF L485-P490 deletion
|
Ovarian Serous Adenocarcinoma
|
BRAF L485-P490 deletion
|
Ovarian Serous Adenocarcinoma
|
LY3009120 Sensitive: D – Preclinical
|
LY3009120 Sensitive: D – Preclinical
|
PRMT1 underexpression
|
Ovarian Serous Adenocarcinoma
|
PRMT1 underexpression
|
Ovarian Serous Adenocarcinoma
|
carboplatin Sensitive: D – Preclinical
|
carboplatin Sensitive: D – Preclinical
|
PRMT1 underexpression
|
Ovarian Serous Adenocarcinoma
|
PRMT1 underexpression
|
Ovarian Serous Adenocarcinoma
|
cisplatin Sensitive: D – Preclinical
|
cisplatin Sensitive: D – Preclinical
|